ExpreS2ion announces the start of the exercise period for warrants of series TO 8
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 7 September 2023 - ExpreS[2]ion Biotech Holding AB ("ExpreS[2]ion" or the "Company") announces that today begins the exercise period for the warrants of series TO 8 (the "Warrants"), which were issued in connection